drugset
drugset / Trial / NCT01705249

Bleeding Profile With Continuous Hormone Replacement Therapy of Activelle® in Postmenopausal Women

NCT01705249 ↗

Phase 4 Completed 191 enrolled Novo Nordisk A/S
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is conducted in Europe. The aim of this study is to investigate the bleeding profile after switch from Trisekvens® to Activelle® (1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)).

Timeline

Start
2001-08-14
Primary completion
2003-06-06
Completion
2003-06-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Estradiol Other / unclassified 1 mg —
Subject Norethindrone Unknown 0.5 mg —

Indications

No indication recorded.